Skip to main content

Advertisement

SpringerLink
Log in

Serum adiponectin levels may be associated with the pathogenesis of hepatocellular carcinoma

  • Research Article
  • Published:
Tumor Biology

Abstract

The aim of the meta-analysis described below was to investigate the correlation between serum levels of adiponectin (ADPN) and the pathogenesis of hepatocellular carcinoma (HCC). Relevant studies about serum ADPN levels and the pathogenesis of HCC were identified by searching electric databases and by manual search. The included studies were selected in strict accordance with the inclusion and exclusion criteria. Detailed criteria were described in “Materials and methods” section. Statistical analyses were conducted with the STATA 12.0 statistical software (StataCorp, College Station, TX, USA). A total of nine studies were incorporated into this meta-analysis after careful consideration, including 705 HCC patients and 1390 healthy controls. This meta-analysis demonstrated that the serum ADPN levels in HCC patients were significantly higher than those in healthy controls (standard mean difference (SMD) = 0.97, 95 % confidence intervals (CI) = 0.02∼1.93, P < 0.05). The result of subgroup analysis by ethnicity revealed that serum ADPN levels in Caucasians and Asians were both obviously higher than those in healthy controls (Caucasians: SMD = 0.51, 95 % CI = 0.30∼0.73, P < 0.001; Asians: SMD = 0.49, 95 % CI = 0.06∼0.91, P < 0.05), but in Africans, the differences between HCC patients and controls had no statistical significance (SMD = 2.64, 95 % CI = −3.01∼8.30, P = 0.36). The evidence obtained by this meta-analysis suggests that serum ADPN levels are associated with the pathogenesis of HCC. Further conclusion might be that increased serum levels of ADPN can inhibit tumor growth and play a protective role in the development of HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264–73. e1.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Blum HE. Hepatocellular carcinoma: HCC. Hepat Mon. 2011;11(2):69–70.

    PubMed  PubMed Central  Google Scholar 

  3. Kanai F, Yoshida H, Tateishi R, Sato S, Kawabe T, Obi S, et al. A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2011;67(2):315–24.

    Article  CAS  PubMed  Google Scholar 

  4. Bovio G, Fonte ML, Baiardi P. Prevalence of upper gastrointestinal symptoms and their influence on nutritional state and performance status in patients with different primary tumors receiving palliative care. Am J Hosp Palliat Care. 2014;31(1):20–6.

    Article  PubMed  Google Scholar 

  5. Jiang GQ, Qian JJ, Yao J, Jin SJ, Bai DS. Acute pancreatitis and obstructive jaundice as initial complaints of hepatocellular carcinoma: case report. World J Surg Oncol. 2014;12:13.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212–36.

    Article  PubMed  Google Scholar 

  7. Parikh S, Hyman D. Hepatocellular cancer: a guide for the internist. Am J Med. 2007;120(3):194–202.

    Article  PubMed  Google Scholar 

  8. Wang SN, Lee KT, Ker CG. Leptin in hepatocellular carcinoma. World J Gastroenterol. 2010;16(46):5801–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Buechler C, Wanninger J, Neumeier M. Adiponectin, a key adipokine in obesity related liver diseases. World J Gastroenterol. 2011;17(23):2801–11.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Uribe M, Zamora-Valdes D, Moreno-Portillo M, Bermejo-Martinez L, Pichardo-Bahena R, Baptista-Gonzalez HA, et al. Hepatic expression of ghrelin and adiponectin and their receptors in patients with nonalcoholic fatty liver disease. Ann Hepatol. 2008;7(1):67–71.

    CAS  PubMed  Google Scholar 

  11. Fukushima N, Kuromatsu R, Arinaga-Hino T, Ando E, Takata A, Sumie S, et al. Adipocytokine involvement in hepatocellular carcinoma after sustained response to interferon for chronic hepatitis C. Hepatol Res. 2010;40(9):911–22.

    Article  CAS  PubMed  Google Scholar 

  12. Kotani K, Wakai K, Shibata A, Fujita Y, Ogimoto I, Naito M, et al. Serum adiponectin multimer complexes and liver cancer risk in a large cohort study in Japan. Asian Pac J Cancer Prev. 2009;10 Suppl:87–90.

  13. Balmer ML, Joneli J, Schoepfer A, Stickel F, Thormann W, Dufour JF. Significance of serum adiponectin levels in patients with chronic liver disease. Clin Sci (Lond). 2010;119(10):431–6.

    Article  CAS  Google Scholar 

  14. Vansaun MN. Molecular pathways: adiponectin and leptin signaling in cancer. Clin Cancer Res. 2013;19(8):1926–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Shin E, Yu YD, Kim DS, Won NH. Adiponectin receptor expression predicts favorable prognosis in cases of hepatocellular carcinoma. Pathol Oncol Res. 2014;20(3):667–75.

    Article  CAS  PubMed  Google Scholar 

  16. Brochu-Gaudreau K, Rehfeldt C, Blouin R, Bordignon V, Murphy BD, Palin MF. Adiponectin action from head to toe. Endocrine. 2010;37(1):11–32.

    Article  CAS  PubMed  Google Scholar 

  17. Kim AY, Lee YS, Kim KH, Lee JH, Lee HK, Jang SH, et al. Adiponectin represses colon cancer cell proliferation via AdipoR1- and -R2-mediated AMPK activation. Mol Endocrinol. 2010;24(7):1441–52.

    Article  CAS  PubMed  Google Scholar 

  18. Byeon JS, Jeong JY, Kim MJ, Lee SM, Nam WH, Myung SJ, et al. Adiponectin and adiponectin receptor in relation to colorectal cancer progression. Int J Cancer. 2010;127(12):2758–67.

    Article  CAS  PubMed  Google Scholar 

  19. Nakajima TE, Yamada Y, Hamano T, Furuta K, Matsuda T, Fujita S, et al. Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci. 2010;101(5):1286–91.

    Article  CAS  PubMed  Google Scholar 

  20. Ye J, Jia J, Dong S, Zhang C, Yu S, Li L, et al. Circulating adiponectin levels and the risk of breast cancer: a meta-analysis. Eur J Cancer Prev. 2014;23(3):158–65.

    Article  CAS  PubMed  Google Scholar 

  21. Chen MJ, Yeh YT, Lee KT, Tsai CJ, Lee HH, Wang SN. The promoting effect of adiponectin in hepatocellular carcinoma. J Surg Oncol. 2012;106(2):181–7.

    Article  CAS  PubMed  Google Scholar 

  22. Nishihara T, Baba M, Matsuda M, Inoue M, Nishizawa Y, Fukuhara A, et al. Adiponectin deficiency enhances colorectal carcinogenesis and liver tumor formation induced by azoxymethane in mice. World J Gastroenterol. 2008;14(42):6473–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Sadik NA, Ahmed A, Ahmed S. The significance of serum levels of adiponectin, leptin, and hyaluronic acid in hepatocellular carcinoma of cirrhotic and noncirrhotic patients. Hum Exp Toxicol. 2012;31(4):311–21.

    Article  CAS  PubMed  Google Scholar 

  24. Liu CJ, Chen PJ, Lai MY, Liu CH, Chen CL, Kao JH, et al. High serum adiponectin correlates with advanced liver disease in patients with chronic hepatitis B virus infection. Hepatol Int. 2009;3(2):364–70.

    Article  PubMed  Google Scholar 

  25. Saxena NK, Fu PP, Nagalingam A, Wang J, Handy J, Cohen C, et al. Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma. Gastroenterology. 2010;139(5):1762–73. 73 e1-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Sharma D, Wang J, Fu PP, Sharma S, Nagalingam A, Mells J, et al. Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. Hepatology. 2010;52(5):1713–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Wang SN, Yang SF, Tsai HH, Lee KT, Yeh YT. Increased adiponectin associated with poor survival in hepatocellular carcinoma. J Gastroenterol. 2014;49(9):1342–51.

    Article  PubMed  Google Scholar 

  28. Zintzaras E, Ioannidis JP. HEGESMA: genome search meta-analysis and heterogeneity testing. Bioinformatics. 2005;21(18):3672–3.

    Article  CAS  PubMed  Google Scholar 

  29. Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol. 2005;28(2):123–37.

    Article  PubMed  Google Scholar 

  30. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.

    Article  PubMed  Google Scholar 

  31. Bishop MJ, Plank G. Simulating photon scattering effects in structurally detailed ventricular models using a Monte Carlo approach. Front Physiol. 2014;5:338.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Song F, Gilbody S. Bias in meta-analysis detected by a simple, graphical test. Increase in studies of publication bias coincided with increasing use of meta-analysis. BMJ. 1998;316(7129):471.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295(6):676–80.

    Article  CAS  PubMed  Google Scholar 

  34. Sumie S, Kawaguchi T, Kuromatsu R, Takata A, Nakano M, Satani M, et al. Total and high molecular weight adiponectin and hepatocellular carcinoma with HCV infection. PLoS One. 2011;6(11):e26840.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Khattab MA, Eslam M, Mousa YI, Ela-adawy N, Fathy S, Shatat M, et al. Association between metabolic abnormalities and hepatitis C-related hepatocellular carcinoma. Ann Hepatol. 2012;11(4):487–94.

    PubMed  Google Scholar 

  36. Guo JW, Ma XB, Wang F, Liu M, Qi YZ, Wang ZG. The study of blood serum adiponectin levels and tumor relations. J Mod Oncol. 2012;20(10):2016–8.

    CAS  Google Scholar 

  37. Aleksandrova K, Boeing H, Nothlings U, Jenab M, Fedirko V, Kaaks R, et al. Inflammatory and metabolic biomarkers and risk of liver and bilary tract cancer. Hepatology. 2014.

  38. Ohki T, Tateishi R, Sato T, Masuzaki R, Imamura J, Goto T, et al. Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. Clin Gastroenterol Hepatol. 2008;6(4):459–64.

    Article  PubMed  Google Scholar 

  39. Jonsson JR, Barrie HD, O’Rourke P, Clouston AD, Powell EE. Obesity and steatosis influence serum and hepatic inflammatory markers in chronic hepatitis C. Hepatology. 2008;48(1):80–7.

    Article  CAS  PubMed  Google Scholar 

  40. Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocr Rev. 2012;33(4):547–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Gardener H, Crisby M, Sjoberg C, Hudson B, Goldberg R, Mendez AJ, et al. Serum adiponectin in relation to race-ethnicity and vascular risk factors in the Northern Manhattan Study. Metab Syndr Relat Disord. 2013;11(1):46–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Lara-Castro C, Fu Y, Chung BH, Garvey WT. Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr Opin Lipidol. 2007;18(3):263–70.

    Article  CAS  PubMed  Google Scholar 

  43. Sugiyama M, Takahashi H, Hosono K, Endo H, Kato S, Yoneda K, et al. Adiponectin inhibits colorectal cancer cell growth through the AMPK/mTOR pathway. Int J Oncol. 2009;34(2):339–44.

    CAS  PubMed  Google Scholar 

  44. Clemmons DR. Insulin-like growth factor binding protein control secretion and mechanisms of action. Adv Exp Med Biol. 1991;293:113–23.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We would like to acknowledge the reviewers for their useful comments on this paper.

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Intensive Care Unit, Jiangsu Province Nantong Tongzhou District People’s Hospital, Nantong, 226300, China

    Rong-Rong Song

  2. Department of Oncology, Jiangsu Province Nantong Tongzhou District People’s Hospital, Construction Road No. 115, Tongzhou District, Nantong, 226300, China

    Xiao-Lin Gu

Authors
  1. Rong-Rong Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiao-Lin Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xiao-Lin Gu.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Song, RR., Gu, XL. Serum adiponectin levels may be associated with the pathogenesis of hepatocellular carcinoma. Tumor Biol. 36, 2983–2992 (2015). https://doi.org/10.1007/s13277-014-2931-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-2931-8

Keywords

Search

Navigation